Research Article

A 2-Year Randomized Controlled Trial of Human Caloric Restriction: Feasibility and Effects on Predictors of Health Span and Longevity

Eric Ravussin, 1 Leanne M. Redman, 1 James Rochon, 2,3 Sai Krupa Das, 4 Luigi Fontana, 5–7 William E. Kraus, 2 Sergei Romashkan, 8 Donald A. Williamson, 1 Simin N. Meydani, 4 Dennis T. Villareal, 5 Steven R. Smith, 1,9 Richard I. Stein, 5 Tammy M. Scott, 4 Tiffany M. Stewart, 1 Edward Saltzman, 4 Samuel Klein, 5 Manju Bhapkar, 2 Corby K. Martin, 1 Cheryl H. Gilhooly, 4 John O. Holloszy, 5 Evan C. Hadley, 8 and Susan B. Roberts 4; for the CALERIE Study Group*

1Pennington Biomedical Research Center, Baton Rouge, Louisiana. 2Duke Clinical Research Institute and Duke University School of Medicine, Durham, North Carolina. 3Rho Federal Systems, Chapel Hill, North Carolina. 4Jean Mayer US Department of Agriculture Human Nutrition Research Center on Aging at Tufts University, Boston, Massachusetts. 5Department of Medicine, Washington University School of Medicine, St. Louis, Missouri. 6Department of Clinical and Experimental Sciences, Brescia University School of Medicine, Italy. 7CEINGE Biotecnologie Avanzate, Napoli, Italy. 8National Institute on Aging, Bethesda, Maryland. 9Translational Research Institute for Metabolism and Diabetes, Florida Hospital and Sanford Burnham Medical Research Institute, Orlando.

*For complete list of CALERIE staff, see online Supplementary Material.

Address correspondence to Evan C. Hadley, MD, National Institute on Aging, Gateway Building, Suite 3C307, Bethesda, MD 20892. Email: ehadley@nih.gov

Received January 28 2015; Accepted April 5 2015.

Decision Editor: Stephen Kritchevsky, PhD

Abstract

Background. Caloric restriction (CR), energy intake reduced below ad libitum (AL) intake, increases life span in many species. The implications for humans can be clarified by randomized controlled trials of CR.

Methods. To determine CR’s feasibility, safety, and effects on predictors of longevity, disease risk factors, and quality of life in nonobese humans aged 21–51 years, 218 persons were randomized to a 2-year intervention designed to achieve 25% CR or to AL diet. Outcomes were change from baseline resting metabolic rate adjusted for weight change (“RMR residual”) and core temperature (primary); plasma triiodothyronine (T3) and tumor necrosis factor-α (secondary); and exploratory physiological and psychological measures.

Results. Body mass index averaged 25.1 (range: 21.9–28.0 kg/m²). Eighty-two percent of CR and 95% of AL participants completed the protocol. The CR group achieved 11.7±0.7 %CR (mean ± standard error) and maintained 10.4±0.4% weight loss. Weight change in AL was negligible. RMR residual decreased significantly more in CR than AL at 12 months (p — .04) but not 24 months (M24). Core temperature change differed little between groups. T3 decreased more in CR at M12 and M24 (p < .001), while tumor necrosis factor-α decreased significantly.
more only at M24 (p = .02). CR had larger decreases in cardiometabolic risk factors and in daily energy expenditure adjusted for weight change, without adverse effects on quality of life.

Conclusions. Sustained CR is feasible in nonobese humans. The effects of the achieved CR on correlates of human survival and disease risk factors suggest potential benefits for aging-related outcomes that could be elucidated by further human studies.

Key Words: Metabolism—Nutrition—Risk factors—Biomarkers—Caloric restriction

Caloric restriction (CR), defined as lessening caloric intake without depriving essential nutrients, beginning early or in mid-life and sustained over the life span, increases longevity and delays or slows progression of multiple age-related diseases in many, but not all, laboratory animal models (1–4). Observational studies of persons voluntarily practicing long-term CR suggest that it favorably affects chronic disease risk factors and has several parallel effects to those in laboratory animals (5). However, the extent to which physiologic and clinical profiles of these self-selected persons reflect effects of CR versus other factors is unknown.

Although clinical trials have yielded considerable information on the effect of weight loss on obesity-related conditions, data from controlled studies in nonobese persons on CR's effects on aging-related outcomes are sparse. In pilot trials for the present study, 6–12 months of CR in overweight but nonobese persons favorably affected risk factors for several conditions affecting health span (6–8). One (7) also provided evidence for metabolic slowing, reduced core temperature, and lowered triiodothyronine (T3), which are effects found in many laboratory animal CR studies and proposed to contribute to CR's effects on life span.

Whether CR extends life span in humans will probably never be determined in randomized clinical trials. However, intermediate-length trials can determine its feasibility, safety, and effects on quality of life, disease risk factors, and predictors of life span. To assess these outcomes over 2 years of CR in young- and middle-aged nonobese men and women, we conducted a three-site randomized controlled trial, CALERIE (Comprehensive Assessment of Long term Effects of Reducing Intake of Energy).

Methods
CALERIE’s rationale and design were described previously (9). Detailed methods are described in the online Supplementary Material.

Study Participants
CALERIE’s age range (21–50 years) was selected to be comparable to the life stage when many “adult onset” CR studies showing substantial effects on life span and aging were begun in rodents. The body mass index (BMI) range (22.0 ≤ BMI < 25.0 kg/m²) was selected to examine CR’s effects in both normal weight and moderately overweight persons. Exclusion criteria (detailed in ref. 9) included significant medical conditions (eg, cardiovascular disease or diabetes), abnormal laboratory markers (eg, elevated potassium, or below-normal hemoglobin levels), present or potential psychiatric or behavioral problems (eg, eating disorders or depressive symptoms), regular use of medications except oral contraceptives, current smoking, a high level of regular physical activity, and pregnancy.

Details on recruitment and screening are reported elsewhere (10) and in Figure 1. CALERIE’s target sample size was 225, with 2:1 ratio randomization to the CR intervention versus an “ad libitum” (AL) control group who continued their habitual diet. Randomization was stratified by site, sex, and BMI dichotomized into normal weight (22.0 ≤ BMI < 25.0 kg/m²) and overweight (25.0 ≤ BMI < 28.0 kg/m²).

Intervention and Adherence Measurements
The intervention was designed to achieve 25% CR, defined as a 25% reduction from AL baseline energy intake. The target level of 25% CR was selected because this degree of CR strongly affects life span and health span in animal models, and was found to be feasible in most participants in a 6-month CALERIE pilot study (7). An intensive 2-year behavioral intervention was designed to facilitate 25% CR (11).

Baseline AL energy intake was assessed by two consecutive 14-day measures of total daily energy expenditure (TDEE) using doubly labeled water (12). Average %CR over 6-month intervals was retrospectively calculated by the intake-balance method with simultaneous measurements of TDEE using doubly labeled water and changes in body composition (13,14). Since these objective measures of %CR were not feasible more than twice a year, participants were provided a “real time proxy” for adherence: a trajectory of weekly expected weight change reaching 15.5% weight loss by 1 year, with an acceptable range of 11.9%–22.1%, followed by weight maintenance. This trajectory was based on a model derived from our phase 1 studies that predicted weekly changes in body weight for 1 year of 25% CR (15).

Outcomes
The two prespecified primary outcomes were selected to test the hypothesis that CR would induce metabolic adaptations, specifically (a) decrease in resting metabolic rate (RMR) adjusted for changes in body composition and (b) decrease in core body temperature. Change in RMR was defined as “RMR residual,” that is, the difference between an individual’s RMR measured by indirect calorimetry during the intervention and RMR predicted from a regression of RMR as a function of fat mass and fat-free mass in participants at baseline. (Details on calculation of RMR residuals are included in the online Supplementary Material) Such metabolic adaptations to CR in laboratory animals have been proposed to slow aging by reducing metabolic production of reactive oxygen species and/or lowering core temperature (1,16). Lower core temperature has also been found to predict human longevity in longitudinal studies (17).

Changes in circulating T3 and tumor necrosis factor-alpha (TNF-α) were prespecified secondary outcomes, based on evidence suggesting relationships of the thyroid axis and inflammatory mediators to longevity and health span and effects of CR on these factors (5,7,18,19). Exploratory outcomes included risk factors for age-related conditions and psychological responses.

Study outcomes were evaluated at baseline, 6, 12, 18, and 24 months with a primary focus on baseline, 12 months, and 24 months. Methods to assess outcomes are described in online Supplementary Material.

Participants were given diaries to record signs, symptoms, and other adverse events occurring during the study. All adverse events were coded using the Medical Dictionary for Medical Affairs (MedDRA), version 14.4. During the study, participants were also monitored for anemia, changes in bone mineral density, and signs of eating disorders.
Statistical Methods

Statistical analysis was performed under intention-to-treat principles following a plan prespecified before initiation of analyses. Observations were included irrespective of protocol violations or poor adherence; data were collected as far as possible beyond discontinuing the intervention and included in the analysis. Between-group differences with respect to demographics and other baseline characteristics, or between those completing versus failing to complete the evaluations, were assessed using the Wilcoxon test and the Fisher exact test. Because observations were taken repeatedly from the same individual, the primary analytic vehicle was a repeated measures analysis (20,21). The dependent variable was the change from baseline to the individual time points, with treatment, time, and the treatment × time interaction as independent variables. Design variables, that is, site, sex, and BMI stratum, as well as the baseline value of the outcome were included as covariates to increase precision. To avoid arbitrary modeling assumptions, time was treated as a categorical variable; similarly, an unstructured model was applied for the covariance matrix among the repeated observations. All hypotheses, for example, main effects, interactions, within-group changes over time, and between-group differences at the individual time points, were tested by defining contrasts among the associated regression parameters. The predicted mean changes ± standard errors are the adjusted values from these contrasts. Because C-reactive protein (CRP) was skewed toward the higher values, we followed the approach in Huffman et al. (22) and analyzed on the natural logarithm scale without adjusting for the baseline value. For any outcome, Type I error was controlled using a hierarchical gatekeeping strategy (23). The treatment × visit interaction term was tested first. If significant, then following standard statistical practice, between-group differences at each time point were tested at $\alpha = .05$. Otherwise a Bonferroni correction was applied at each time point, with the $p$ values adjusted by multiplying the nominal $p$ value by the number of tests (truncated at $1.0$) (24). Within-group changes from baseline to the follow-up visits, however, fell outside this hierarchy and were always protected by a Bonferroni correction. Supplemental analyses to determine whether changes over time in one variable were associated with that in another were performed using the Spearman correlation. All analyses were performed using SAS version 9.2 (Cary, NC). Results are reported as mean ± standard error except when otherwise noted.

Results

Participants

Totally, 238 individuals were eligible and commenced baseline assessments; 220 were randomized and 218 started the intervention (Figure 1), with 82% of CR and 95% of AL completing the 2-year protocol. The cohort was predominantly female (69.7%) and Caucasian (77.1%) with ages from 20.7 to 50.8 years. Mean ± standard deviation BMI was $25.1 \pm 1.7$ kg/m², and was slightly lower among women. The cohort had normal blood pressures, fasting blood glucose, insulin and lipids at baseline. No significant differences were observed between groups at baseline. Complete demographic, anthropometric, and clinical characteristics at baseline are presented in online Supplementary eTable 1.

Adherence and Weight Loss

Baseline mean ± standard error energy intake (assessed as TDEE during weight stability) did not differ significantly between AL and CR: $2,390 \pm 45$ and $2,467 \pm 34$ kcal/d, respectively ($p = .15$). Mean daily energy intake over the first 6 months of the intervention declined...
Table 1. Baseline Values and Changes From Baseline for Energy Metabolism Variables and Prespecified Hormones and Markers of Inflammation in Control (AL) and Caloric Restriction (CR) Groups

<table>
<thead>
<tr>
<th>Outcome</th>
<th>AL</th>
<th>CR</th>
<th>Between-Group p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TDEE, kcal/d</strong></td>
<td>2,390 (45)</td>
<td>2,467 (34)</td>
<td>.15</td>
</tr>
<tr>
<td>Baseline</td>
<td>2,390 (45)</td>
<td>2,467 (34)</td>
<td>.15</td>
</tr>
<tr>
<td>Δ Year 1 average</td>
<td>−20 (24)</td>
<td>−342 (19)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Δ Year 2 average</td>
<td>−4 (25)</td>
<td>−173 (20)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Δ Year 1 and 2 average</td>
<td>−11 (23)</td>
<td>−257 (18)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td><strong>RMR, kcal/d</strong></td>
<td>1,393 (24)</td>
<td>1,418 (17)</td>
<td>.33</td>
</tr>
<tr>
<td>Baseline</td>
<td>1,393 (24)</td>
<td>1,418 (17)</td>
<td>.33</td>
</tr>
<tr>
<td>Δ Month 12</td>
<td>−1 (13)</td>
<td>−83 (10)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Δ Month 24</td>
<td>−7 (16)</td>
<td>−71 (12)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td><strong>24-h core temperature, °C</strong></td>
<td>37.0 ± (0.03)</td>
<td>37.0 ± (0.02)</td>
<td>.41</td>
</tr>
<tr>
<td>Baseline</td>
<td>37.0 ± (0.03)</td>
<td>37.0 ± (0.02)</td>
<td>.41</td>
</tr>
<tr>
<td>Δ Month 12</td>
<td>−0.03 ± (0.02)</td>
<td>−0.05 ± (0.02)</td>
<td>.06</td>
</tr>
<tr>
<td>Δ Month 24</td>
<td>−0.02 ± (0.02)</td>
<td>−0.05 ± (0.02)</td>
<td>.02</td>
</tr>
<tr>
<td><strong>Hormones and inflammation</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Triiodothyronine, ng/dL&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Baseline</td>
<td>112.6 ± (2.8)</td>
<td>115.6 ± (2.1)</td>
</tr>
<tr>
<td>Δ Month 12</td>
<td>−8.1 ± (2.3)</td>
<td>−18.4 ± (1.8)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Δ Month 24</td>
<td>−14.1 ± (2.0)</td>
<td>−25.0 ± (1.6)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>TSH, uIU/mL&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Baseline</td>
<td>1.56 ± (0.12)</td>
<td>1.53 ± (0.11)</td>
</tr>
<tr>
<td>Δ Month 12</td>
<td>−0.02 ± (0.07)</td>
<td>−0.21 ± (0.05)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Δ Month 24</td>
<td>−0.15 ± (0.07)</td>
<td>−0.23 ± (0.05)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>TNF-α, pg/mL&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Baseline</td>
<td>3.1 ± (0.1)</td>
<td>3.5 ± (0.1)</td>
</tr>
<tr>
<td>Δ Month 12</td>
<td>−0.34 ± (0.12)</td>
<td>−0.30 ± (0.09)</td>
<td>.002</td>
</tr>
<tr>
<td>Δ Month 24</td>
<td>−0.38 ± (0.14)</td>
<td>−0.77 ± (0.11)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>ln (CRP, μg/mL)</td>
<td>Baseline</td>
<td>1.09 ± (0.2)</td>
<td>1.48 ± (0.3)</td>
</tr>
<tr>
<td>Δ Month 12&lt;sup&gt;b&lt;/sup&gt;</td>
<td>0.003 ± (0.139)</td>
<td>−0.506 ± (0.105)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Δ Month 24&lt;sup&gt;b&lt;/sup&gt;</td>
<td>−0.037 ± (0.125)</td>
<td>−0.458 ± (0.096)</td>
<td>&lt;.001</td>
</tr>
</tbody>
</table>

Notes: AL = ad libitum diet; CR = Caloric Restriction; RMR = resting metabolic rate; TDEE = total daily energy expenditure; TDEI = total daily energy intake; TNF-α = tumor necrosis factor-α; TSH = thyroid-stimulating hormone. *Prespecified primary outcome. †Prespecified secondary outcome.

*Baseline values are the observed mean (standard error); change scores are the least-squares adjusted means (standard error).
†Within-group p value tests for a significant change from baseline to the follow-up time point in that group; between-group p value tests for a significant between-group difference in the change score at the time point. All p values reflect Bonferroni corrections, truncated at 1.0, as appropriate (see text).
‡Baseline TDEE = baseline TDEI; Δ Year 1 average = average TDEI during BL-M12 interval, minus baseline TDEE; Δ Year 2 average = average TDEI during M12-M24 interval, minus baseline TDEE; Δ Year 1 and 2 average = average TDEI during BL-M24 interval, minus baseline TDEE. (See Methods in Supplementary Material.)

High-sensitivity CRP was analyzed on the natural log scale without adjusting for the baseline value (see Statistical Methods).

from baseline (Figure 2A) in CR by 480 ± 20 kcal/d during the first 6 months of intervention, then stabilized at approximately 234 ± 19 kcal/d below baseline for the remainder of the trial, resulting in CR averaging 11.7 ± 0.7% over 2 years (19.5 ± 0.8% during the first 6 months and 9.1 ± 0.7% on average for the remainder of the study). ΔCR in the AL group was 1.3 ± 1.1% over the first 12 months and 0.4 ± 1.1% over the second 12 months, p < .001 versus CR. Weight loss (Figure 2B) was significant in CR: 7.1 ± 0.2 kg (9.9 ± 0.3%) at 6 months, 8.3 ± 0.3 kg at 12 months (11.5 ± 0.4%), and 7.6 ± 0.3 kg at 24 months (10.4 ± 0.4%), all p < .0001. The decrease in lean body mass from baseline was 2.0 ± 0.1 kg (4.2 ± 0.2%) at 6 months, 2.0 ± 0.1 kg at 12 months (4.3 ± 0.3%) and 2.0 ± 0.2 kg at 24 months (4.4 ± 0.3%), all p < .001. Change in weight was predominantly due to body fat loss (74% fat at 6 months, 74% fat at 12 months, and 69% fat at 24 months).

Safety and Quality of Life
There were no deaths and eight serious adverse events (seven AL, one CR), none considered to be related to the intervention. Six women (three AL, three CR) became pregnant and were permanently withdrawn according to the protocol. Eight CR participants were temporarily discontinued from the intervention for safety concerns: one for a BMI <18.5 kg/m², three for a decrease in bone mineral density ≥5% from baseline, and four for treatment-resistant anemia. Five resumed the intervention after these problems resolved. The bone mineral density deficit in one participant and anemia in two participants did not resolve and they were permanently withdrawn from the intervention. The small bone mineral density decreases (lumbar spine and femoral neck) in the CR group significantly exceeded those in the AL control group. Monitoring for eating disorders found no incident events. Adverse events are summarized in online Supplementary.
The effects of caloric restriction (CR) on a broad range of quality of life variables including mood, self-reported hunger, sexual function, and cognitive function, using validated measures of all constructs. These results are shown in online Supplementary eTable 3.

**RMR, TDEE, and Core Temperature**

Effects on our two prespecified primary outcomes (RMR residual and core temperature) are presented in Table 1 and Figure 3. Although decreases from baseline in absolute RMR in CR (5.9±0.7% and 5.0±0.9% at 12 and 24 months, respectively) significantly exceeded those in AL, RMR residual decreased significantly more in CR compared with AL at 12 months (48±9 vs 14±12 kcal/d in AL, p=.04) (Figure 3A), representing a larger decline in RMR than predicted on the basis of changes in fat-free and fat mass, but decreases did not differ significantly between CR and AL at 24 months. TDEE decreased significantly more in CR than AL (Table 1). TDEE residual also decreased by 164±19 and 157±21 kcal/d at 12 and 24 months, respectively, significantly more than in AL (Figure 3B; 44±26 and 38±27 kcal/d; p<.001 at 12 months and p=.003 at 24 months). Mean 24-hour core temperature decreased from baseline at 12 and 24 months in CR (Table 1), but the small declines did not differ significantly from the change in AL.

**Thyroid Axis and Inflammation**

Effects on our two prespecified secondary outcomes (circulating T3 and TNF-α) are presented in Table 1. The substantial decreases from baseline within the normal range in circulating T3 in CR (16±1.5% at month 12, 22±1.4% at 24 months) significantly exceeded changes in AL. Thyroid-stimulating hormone reductions in CR also significantly exceeded those in AL at 12 months. In both groups, TNF-α concentration decreased from baseline at 12 months, more so by 24 months (23±3.3% CR, 11±4.2% AL). The decline from baseline to 24 months was significantly greater in CR versus AL. The marked decreases in high-sensitivity CRP from baseline to both time points in CR significantly exceeded changes in AL.

**Cardiometabolic Risk Factors**

CR broadly affected cardiometabolic risk factors. The decreases in triglycerides and total cholesterol (Figure 4A and B) in CR significantly exceeded those in AL, as did decreases in low-density lipoprotein cholesterol (data not shown). The increase in high-density lipoprotein cholesterol was significantly greater in CR than in AL at 24 months only. Declines in systolic and diastolic blood pressures were also significantly greater in CR than in AL (p=.001), which showed a tendency toward an increase (mean blood pressure shown in Figure 4C). Improvements in glucose control (HOMA-IR) in CR were significantly greater than changes in AL (Figure 4).
AL = ad libitum; CR = caloric restriction.

Values are adjusted means ± standard error. p values refer to differences in change over time between the AL and CR groups.

Figure 3. Changes in resting metabolic rate (RMR) (Panel A) and total daily energy expenditure (TDEE) (Panel B) not attributable to changes in fat-free mass and fat mass at month 12 and month 24 in the AL group (black bars) and the CR group (gray bars). "Measured – Predicted" refers to the difference between measured values and the values predicted by our regression model based on baseline relationships of fat-free mass and fat mass to RMR and TDEE (often called residuals; see Methods section). Values are adjusted means ± standard error. p values refer to differences in change over time between the AL and CR groups. AL = ad libitum; CR = caloric restriction.

The effects of CR in this study on multiple cardiometabolic risk factors that were measured as exploratory outcomes were consistently in the direction considered "favorable," and extend previous similar findings on effects of weight loss in more overweight or obese persons to leaner individuals. Changes in such risk factors of the magnitude described by the present study may be considered a positive finding in light of the consistent null findings reported in exploratory outcome analyses in other CR studies. However, given self-reported activity measures' limitations in accuracy and sensitivity to change, additional data are needed to clarify the degrees to which CR affects physical activity levels and metabolic efficiency of physical activity.

Overall, great caution is indicated in speculations about the relationships of our metabolic findings to human longevity. Nevertheless, it is noteworthy that long-term human longitudinal data indicate a positive relationship between mortality rates and energy expenditure independent of BMI (28) or body weight (29).

The decrease in T3 and thyroid-stimulating hormone concentrations in CR participants is of interest in light of findings on the relationship of lowered thyroid activity to longevity in human and animal studies (18). However, a mechanistic role of lowered thyroid function in CR’s effects on longevity in laboratory animals, or in human life span or health span, has not been established. The observed reduction in inflammatory markers (TNF-α and high-sensitivity CRP) parallels several animal CR studies (19). Lowered TNF-α and CRP have also been found in observational studies of persons practicing long-term CR (30). However, human family and heritability studies do not provide consistent evidence for a relationship of CRP and TNF-α levels with longevity (31–33), although many age-related disorders in humans are associated with elevated levels of these markers (33,34). Particularly since baseline concentrations of these analytes in our study were within normal ranges, the significance of our observed effects on these markers for subsequent aging and health span is uncertain.

The decrease in T3 and thyroid-stimulating hormone concentrations in CR participants is of interest in light of findings on the relationship of lowered thyroid activity to longevity in human and animal studies (18). However, a mechanistic role of lowered thyroid function in CR’s effects on longevity in laboratory animals, or in human life span or health span, has not been established. The observed reduction in inflammatory markers (TNF-α and high-sensitivity CRP) parallels several animal CR studies (19). Lowered TNF-α and CRP have also been found in observational studies of persons practicing long-term CR (30). However, human family and heritability studies do not provide consistent evidence for a relationship of CRP and TNF-α levels with longevity (31–33), although many age-related disorders in humans are associated with elevated levels of these markers (33,34). Particularly since baseline concentrations of these analytes in our study were within normal ranges, the significance of our observed effects on these markers for subsequent aging and health span is uncertain.

A long-standing issue in the interpretation of CR studies has been the degree to which its effects are mediated by lowered energy intake per se or by weight loss. This issue can be addressed directly by intervention studies that include treatment arms yielding equivalent degrees
of weight loss produced by CR versus increased energy expenditure from physical activity. A rodent study with such a design found that CR extended both maximum and mean life span, while increased physical activity extended only mean life span (36). A CALERIE pilot study with an analogous design found that CR and physical activity had parallel effects on a variety of metabolic outcomes (8) and on many, but not all, coronary heart disease risk factors (37), some of which were improved significantly only by CR. Although CALERIE did not include multiple treatment arms to address this issue directly, future analyses of CALERIE data on weight loss, %CR, and outcomes could provide additional insights on this point.

In summary, this study provides the first evidence from a randomized controlled trial that sustained CR is both feasible and without adverse effects on quality of life in nonobese humans. The intervention achieved a degree of CR sufficient to affect some, but not all, potential modulators of longevity that have been induced by CR in laboratory animal studies, to influence factors associated with longevity in human observational studies, and to diminish risk factors for age-related cardiovascular and metabolic diseases. The potential impact of CR on human life span and health span could be clarified by studies assessing effects of differing degrees and durations of CR in humans, as well as laboratory animal and human studies to clarify the role of mechanisms implicated in the present findings.

**Supplementary Material**

Supplementary material can be found at: [http://biomedgerontology.oxfordjournals.org/](http://biomedgerontology.oxfordjournals.org/)

**Funding**

This study was supported by the National Institute on Aging; National Institute of Diabetes and Digestive and Kidney Diseases; National Institutes of Health Cooperative Agreements
Acknowledgments


Conflict of Interest

The authors have no competing conflicts of interest related to the data reported herein.

References